Summary
132.08 2.10(1.62%)05/13/2024
Transmedics Group Inc (TMDX)
Transmedics Group Inc (TMDX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.18 | 35.04 | 41.11 | 44.13 | 108.87 | 78.90 | 382.73 | 467.58 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 126.91 | |
| Open | 132.45 | |
| High | 132.96 | |
| Low | 125.86 | |
| Volume | 801,016 | |
| Change | -5.54 | |
| Change % | -4.18 | |
| Avg Volume (20 Days) | 1,080,665 | |
| Volume/Avg Volume (20 Days) Ratio | 0.74 | |
| 52 Week Range | 36.42 - 132.96 | |
| Price vs 52 Week High | -4.55% | |
| Price vs 52 Week Low | 248.46% | |
| Range | -4.18 | |
| Gap Up/Down | -0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,349 | |
| EBIDTA | -23,001,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 45.60 | |
| Book Value | 2.8290 | |
| Earnings Per Share | -1.3790 | |
| EPS Estimate Current Quarter | -0.3600 | |
| EPS Estimate Next Quarter | -0.3000 | |
| EPS Estimate Current Year | -1.5700 | |
| EPS Estimate Next Year | -0.9300 | |
| Diluted EPS (TTM) | -1.3790 | |
| Revenues | ||
| Profit Marging | -1.3415 | |
| Operating Marging (TTM) | -1.2046 | |
| Return on asset (TTM) | -0.1463 | |
| Return on equity (TTM) | -0.4025 | |
| Revenue TTM | 28,221,000 | |
| Revenue per share TTM | 1.0280 | |
| Quarterly Revenue Growth (YOY) | -0.2430 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 16,635,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.8445 | |
| Revenue Enterprise Value | 19.4317 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 27,768,300 | |
| Shares Float | 26,529,569 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.50 | |
| Institutions (%) | 71.14 | |
05/06 10:01 EST - Zacks Investment Research
Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now?
Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now?
Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
05/03 13:21 EST - Zacks Investment Research
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
05/03 10:16 EST - Zacks Investment Research
TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?
TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TransMedics Group, Inc. (TMDX) Soars to 52-Week High, Time to Cash Out?
TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
05/01 00:41 EST - Seeking Alpha
TransMedics Group, Inc. (TMDX) Q1 2024 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Suraj Kalia - Oppenheimer & Company Operator Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TransMedics Group, Inc. (TMDX) Q1 2024 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Suraj Kalia - Oppenheimer & Company Operator Good afternoon and welcome to the TransMedics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
04/30 18:35 EST - Zacks Investment Research
TransMedics (TMDX) Beats Q1 Earnings and Revenue Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.08 per share a year ago.
TransMedics (TMDX) Beats Q1 Earnings and Revenue Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.08 per share a year ago.
04/26 10:21 EST - Zacks Investment Research
Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Exploring Analyst Estimates for TransMedics (TMDX) Q1 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
04/24 19:05 EST - Zacks Investment Research
TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.
TransMedics (TMDX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.
04/23 11:07 EST - Zacks Investment Research
TransMedics (TMDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics (TMDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/22 19:21 EST - Zacks Investment Research
TransMedics (TMDX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.
TransMedics (TMDX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.
04/15 19:21 EST - Zacks Investment Research
TransMedics (TMDX) Flat As Market Sinks: What You Should Know
TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.
TransMedics (TMDX) Flat As Market Sinks: What You Should Know
TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.
04/12 16:30 EST - InvestorPlace
Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024
Whether you believe them or not, analyst ratings have long been a strong indicator of the stock price's direction. There is a direct correlation between how Wall Street analysts rate a stock and how it performs.
Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024
Whether you believe them or not, analyst ratings have long been a strong indicator of the stock price's direction. There is a direct correlation between how Wall Street analysts rate a stock and how it performs.
04/12 06:30 EST - InvestorPlace
3 Must-Own Stocks for Sustained Growth Over the Next 18 Months
The bull market continues, and the S&P 500 is hardly giving up any gains. Indeed, the momentum from the October 2023 lows has been incredible.
3 Must-Own Stocks for Sustained Growth Over the Next 18 Months
The bull market continues, and the S&P 500 is hardly giving up any gains. Indeed, the momentum from the October 2023 lows has been incredible.
03/19 01:46 EST - Seeking Alpha
TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
FY2023: TransMedics' revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone. TransMedics' Organ Care System (OCS) could drive transplant volumes by expanding the donor pool through increased utilization of marginal (including DCD) organs. As the only FDA-approved multi-organ platform, TransMedics faces relatively limited competition at the moment and looks well positioned to establish a market leading position.
TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
FY2023: TransMedics' revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone. TransMedics' Organ Care System (OCS) could drive transplant volumes by expanding the donor pool through increased utilization of marginal (including DCD) organs. As the only FDA-approved multi-organ platform, TransMedics faces relatively limited competition at the moment and looks well positioned to establish a market leading position.
03/14 10:51 EST - Zacks Investment Research
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
03/12 14:14 EST - Seeking Alpha
TransMedics Group: Huge Opportunity In Organ Transplants
TransMedics Group is transforming the organ transplant landscape with its expansive transplant solutions. The company has a proven technology, FDA approved, making it a rare early commercial-stage investment opportunity. TransMedics has led to double-digit growth in liver, lung, and heart transplants in the U.S., with a market size of over $1.5 billion in 2023.
TransMedics Group: Huge Opportunity In Organ Transplants
TransMedics Group is transforming the organ transplant landscape with its expansive transplant solutions. The company has a proven technology, FDA approved, making it a rare early commercial-stage investment opportunity. TransMedics has led to double-digit growth in liver, lung, and heart transplants in the U.S., with a market size of over $1.5 billion in 2023.
03/03 06:23 EST - The Motley Fool
2 No-Brainer Growth Stocks to Buy With $100 in March
The stock market keeps reaching new heights, but you can still find terrific growth stocks trading for reasonable prices. PubMatic's supply-side advertising platform generates a strong profit, and it has room to grow.
2 No-Brainer Growth Stocks to Buy With $100 in March
The stock market keeps reaching new heights, but you can still find terrific growth stocks trading for reasonable prices. PubMatic's supply-side advertising platform generates a strong profit, and it has room to grow.
03/01 08:45 EST - The Motley Fool
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this year.
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this year.
02/28 16:06 EST - PRNewsWire
TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass. , Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass. , Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
02/26 21:37 EST - Seeking Alpha
TransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call Transcript
TransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call Transcript
02/07 10:28 EST - Seeking Alpha
TransMedics: A Very Expensive Growth Stock
TransMedics has a dominant market position in the organ transplant market due to its revolutionary Organ Care System product, which helps organs survive longer, enabling significantly greater reach. At 15x TTM P/S and 9x NTM P/S, TransMedics stock is expensive but somewhat justified due to its triple-digit revenue growth rate. TransMedics' valuation is in line with Swedish peer, Xvivo Perfusion AB, despite growing significantly faster.
TransMedics: A Very Expensive Growth Stock
TransMedics has a dominant market position in the organ transplant market due to its revolutionary Organ Care System product, which helps organs survive longer, enabling significantly greater reach. At 15x TTM P/S and 9x NTM P/S, TransMedics stock is expensive but somewhat justified due to its triple-digit revenue growth rate. TransMedics' valuation is in line with Swedish peer, Xvivo Perfusion AB, despite growing significantly faster.